Martijn van de Hel has assisted academic hospitals Erasmus MC and LUMC in obtaining approval from the NZa and ACM for the acquisition of joint control over GenomeScan. GenomeScan is a laboratory that provides innovative DNA analyses for diagnostics and genetic laboratory research.
Both the NZa and ACM approved early 2019 that Erasmus MC, together with existing shareholders LUMC and Genomic Investments, may acquire control over GenomeScan.
